Erlonat 150 Tablet: A Powerful Treatment Option

Erlonat 150 Tablet contains the active ingredient Erlotinib, a tyrosine kinase inhibitor used to treat advanced non-small cell lung cancer (NSCLC). This medication specifically targets epidermal growth factor receptor (EGFR) mutations found in NSCLC cells.

The 150mg dose of Erlotinib is prescribed for patients who have not responded well or cannot be treated with standard therapies like surgery and chemotherapy. Its effectiveness lies in inhibiting the signaling pathways associated with uncontrolled cell growth, leading to tumor regression.

Key Features:

* Precise dosage: Erlonat tablets contain a standardized dose of 150mg Erlotinib per tablet for optimal therapeutic effect.
* Proven efficacy: Clinical trials have demonstrated Erlotinib's effectiveness in treating advanced NSCLC, including EGFR-mutant tumors.
* Suitable for specific patients: This medication is prescribed to individuals with NSCLC who haven't benefited from other treatments or have a certain genetic mutation (EGFR) in their cancer cells.

Important Note:
Always consult your doctor before taking this medication and follow the prescribed dosage regimen. This description provides general information, not specific medical advice.

Please remember to always prioritize professional medical guidance for personalized treatment decisions.